Emergent BioSolutions | EBS - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Akebia Therapeutics USD 184.84M 18.4M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amarin USD 122.8M 25.08M 2025-09
ANI Pharmaceuticals USD 285.58M 22.98M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Exelixis USD 482.49M 106.19M 2025-12
Glaxosmithkline GBP 3.3B 303M 2025-09
Heron Therapeutics USD 43.07M 26.55M 2025-09
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Ironwood Pharmaceuticals USD 140.41M 47.56M 2025-09
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Lonza CHF 719M 188M 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Myriad Genetics USD 149.6M 4.2M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Pacira USD 158.54M 10.96M 2025-12
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
United Therapeutics USD 1.56B 217M 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Xoma USD 143.9M 7.68M 2024-06